What are the guidelines for treating hypogonadism (low testosterone) in Alberta, Canada?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

In Alberta, treatment for low testosterone is generally recommended when a patient has both clinical symptoms of hypogonadism and confirmed low serum testosterone levels, specifically when morning total testosterone levels are below 8 nmol/L (230 ng/dL) on at least two separate occasions, along with symptoms such as decreased libido, erectile dysfunction, fatigue, decreased muscle mass, or depressed mood, as supported by the most recent study 1.

Key Considerations

  • The primary treatment is testosterone replacement therapy (TRT), which comes in several forms: intramuscular injections (testosterone cypionate 50-100mg weekly or testosterone enanthate 100-200mg every 2 weeks), transdermal gels (AndroGel or Testim 50-100mg daily), or testosterone patches (2-6mg daily) 2.
  • Before initiating treatment, patients should undergo baseline assessments including PSA, hematocrit, and liver function tests, and be monitored at 3,6, and 12 months, then annually, checking testosterone levels, hematocrit, PSA, and liver function 3.
  • TRT is contraindicated in men with prostate cancer, severe lower urinary tract symptoms, hematocrit >54%, unstable heart disease, or those desiring fertility, as highlighted in 4 and 5.

Treatment Goals

  • The goal of treatment is to restore testosterone levels to the mid-normal range (14-17 nmol/L) while alleviating symptoms, as testosterone plays a crucial role in maintaining male secondary sexual characteristics, bone density, muscle mass, and overall well-being.
  • Alternative approaches, such as clomiphene citrate and human chorionic gonadotropin, may be considered for young hypogonadal patients who desire future fertility, as discussed in 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.